Big lessons from the little Akkermansia muciniphila in hepatocellular carcinoma

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 14, 2025

Hepatocellular carcinoma (HCC) is the most frequently occurring type of liver tumor and considered one common primary malignant neoplasms. The prognosis for HCC dismal because its complicated etiology high level medication resistance. Immunotherapy presently regarded as effective therapeutic options HCC; nevertheless, disturbance intestinal flora, immunotherapy shows low antitumor efficacy. An increasing body research indicates that particularly Akkermansia muciniphila ( A. ), vital treatment tumors. Studies have demonstrated diminished effectiveness in cancer patients associated with a reduction levels, suggesting levels significantly enhance efficacy immunotherapy. functions gut probiotic can treat prevent wide range illnesses, including cancer. Consequently, preserving abundance enough to lower danger developing disorders. In this review, we critically evaluate current on , focus biological properties functions. different illnesses treats were then discussed, way it works This review aims give novel plan well theoretical foundation improving

Language: Английский

---

Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 1, 2025

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with limited treatment options at advanced stages. The gut microbiota, diverse community microorganisms residing in the gastrointestinal tract, plays pivotal role regulating immune responses through gut-liver axis. Emerging evidence underscores its impact on HCC progression and efficacy immunotherapy. This review explores intricate interactions between microbiota system HCC, focus key cells pathways involved tumor immunity. Additionally, it highlights strategies for modulating – such as fecal transplantation, dietary interventions, probiotics potential approaches to enhancing immunotherapy outcomes. A deeper understanding these mechanisms could pave way novel therapeutic aimed improving patient prognosis.

Language: Английский

---

Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases II

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 904 - 904

Published: April 8, 2025

Hepatobiliary diseases, including liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and cholestatic disorders, pose significant global health challenges due to their complex pathogenesis limited treatment options [...]

Language: Английский

---

Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: Oct. 5, 2024

Language: Английский

---